Skip navigation

DSpace

機構典藏 DSpace 系統致力於保存各式數位資料(如:文字、圖片、PDF)並使其易於取用。

點此認識 DSpace
DSpace logo
English
中文
  • 瀏覽論文
    • 校院系所
    • 出版年
    • 作者
    • 標題
    • 關鍵字
    • 指導教授
  • 搜尋 TDR
  • 授權 Q&A
    • 我的頁面
    • 接受 E-mail 通知
    • 編輯個人資料
  1. NTU Theses and Dissertations Repository
  2. 醫學院
  3. 藥學專業學院
  4. 藥學系
請用此 Handle URI 來引用此文件: http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/15994
完整後設資料紀錄
DC 欄位值語言
dc.contributor.advisor陳基旺
dc.contributor.authorChun-Wei Loen
dc.contributor.author羅浚瑋zh_TW
dc.date.accessioned2021-06-07T17:57:29Z-
dc.date.copyright2012-09-19
dc.date.issued2012
dc.date.submitted2012-08-13
dc.identifier.citation1.Omori, K.; Kotera, J. Overview of PDEs and their regulation. Circ. Res. 2007, 100, 309-27.
2.Ghofrani, H.-A.; Grimminger, F. Modulating cGMP to treat lung diseases. Handb. Exp. Pharmacol. 2009, 191, 469-483.
3.Bender, A. T.; Beavo, J. A. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol. Rev. 2006, 58, 488-520.
4.Conti, M.; Beavo, J. Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu. Rev. Biochem. 2007, 76, 481-511.
5.Halpin, D. M. ABCD of the phosphodiesterase family interaction and differential activity in COPD. Int. J. Chron. Obstruct. Pulmon. Dis. 2008, 3, 543-561.
6.Kodimuthali, A.; Jabaris, S. S. L.; Pal, M. Recent Advances on Phosphodiesterase 4 Inhibitors for the Treatment of Asthma and Chronic Obstructive Pulmonary Disease. J. Med. Chem. 2008, 51, 5471-5489.
7.Ghofrani, H. A.; Osterloh, I. H.; Grimminger, F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat. Rev. Drug Discov. 2006, 5, 689-702.
8.Dorsey, P.; Keel, C.; Klavens, M.; Hellstrom, W. J. Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction. Expert Opin. Pharmacother. 2010, 11, 1109-1122.
9.Rotella, D. P. Phosphodiesterase 5 inhibitors: current status and potential applications. Nat. Rev. Drug Discov. 2002, 1, 674-82.
10.Bischoff, E. Potency, selectivity, and consequences of nonselectivity of PDE inhibition. Int. J. Impot. Res. 2004, 16 Suppl 1, S11-4.
11.Konstantinos, G.; Petros, P. Phosphodiesterase-5 Inhibitors: Future Perspectives Curr. Pharm. Des. 2009, 15, 3540-3551.
12.Segal, R.; Burnett, A. L. Avanafil for the treatment of erectile dysfunction. Drugs Today (Barc) 2012, 48, 7-15.
13.Menniti, F. S.; Ren, J.; Coskran, T. M.; Liu, J.; Morton, D.; Sietsma, D. K.; Som, A.; Stephenson, D. T.; Tate, B. A.; Finklestein, S. P. Phosphodiesterase 5A Inhibitors Improve Functional Recovery after Stroke in Rats: Optimized Dosing Regimen with Implications for Mechanism. J. Pharmacol. Exp. Ther. 2009, 331, 842-850.
14.Menniti, F. S.; Faraci, W. S.; Schmidt, C. J. Phosphodiesterases in the CNS: targets for drug development. Nat. Rev. Drug Discov. 2006, 5, 660-70.
15.Pomara, G.; Morelli, G. Inhibition of phosphodiesterase 11 (PDE11) impacts on sperm quality. Int. J. Impot. Res. 2005, 17, 385-6; author reply 387.
16.Lai, S.-Y. Design, synthesis and biological evaluation of 1-benzyl-4-phenyl-1H-quinazolin-2-one derivatives as phosphodiesterase inhibitors. Ph.D. Thesis, National Taiwan University, Taiwan, R. O. C., 2007.
17.Chang, C.-Y. Design and synthesis of 4-aryl-1-benzyl-1H-quinazolin-2-one an dual phosphodiesterase 4 and 5 inhibitors. Master thesis, National Taiwan University, Taiwan, R. O. C., 2010.
18.Aoki, M.; Kobayashi, M.; Ishikawa, J.; Saita, Y.; Terai, Y.; Takayama, K.; Miyata, K.; Yamada, T. A Novel Phosphodiesterase Type 4 Inhibitor, YM976 (4-(3-Chlorophenyl)-1,7-diethylpyrido[2,3-d]pyrimidin-2(1H)-one), with Little Emetogenic Activity. J. Pharmacol. Exp. Ther. 2000, 295, 255-260.
19.Puterov'a, Z.; Bobula, T.; V'egh, D. Synthesis of novel 5-chlorinated 2-aminothiophenes using 2,5-dimethylpyrrole as an amine protecting group. J. Heterocyclic Chem. 2008, 45, 201-207.
20.Pissarnitski, D. Phosphodiesterase 5 (PDE 5) inhibitors for the treatment of male erectile disorder: attaining selectivity versus PDE6. Med. Res. Rev. 2006, 26, 369-95.
21.Castanet, A. S.; Colobert, F.; Broutin, P. E. Mild and regioselective iodination of electron-rich aromatics with N-iodosuccinimide and catalytic trifluoroacetic acid. Tetrahedron Lett. 2002, 43, 5047-5048.
22.McKinley, N. F.; O'Shea, D. F. Efficient Synthesis of Aryl Vinyl Ethers Exploiting 2,4,6-Trivinylcyclotriboroxane as a Vinylboronic Acid Equivalent. J. Org. Chem. 2004, 69, 5087-5092.
23.Pletnev, A. A.; Tian, Q.; Larock, R. C. Carbopalladation of Nitriles Synthesis of Benzocyclic Ketones and Cyclopentenones via Pd-Catalyzed Cyclization of ω-(2-Iodoaryl)alkanenitriles and Related Compounds. J. Org. Chem. 2002, 67, 9276-9287.
24.Ottosen, E. R.; Sorensen, M. D.; Bjorkling, F.; Nielsen, T. S.; Fjording, M. S.; Aaes, H.; Binderup, L. Synthesis and Structure−Activity Relationship of Aminobenzophenones. A Novel Class of p38 MAP Kinase Inhibitors with High Antiinflammatory Activity. J. Med. Chem. 2003, 46, 5651-5662.
25.Slocum, D. W.; Reece, T. L.; Sandlin, R. D.; Reinscheld, T. K.; Whitley, P. E. Metalations utilizing aryllithiums; ortho-functionalization of p-bromoanisole (pBrA). Tetrahedron Lett. 2009, 50, 1593-1595.
26.Auberson, Y.; Zimmermann, K.; Hintermann, S. Benzo[1,2,5]oxadiazoles and benzo [1,2,5]thiadiazoles useful as histopathological staining agents, imaging agents and biomarkers. WO2004087684 2004.
27.Tibor, M.; Simon Neil, P.; Philip Henry Gaunt, S. 4-benzoyl isoxazoles derivatives and their use as herbicides. US632315 (B1), 2001.
28.Perkins, R. L.; Sweet, A. J. Benzonitriles and process for making. US2044015, 1933.
29.Verkade, P. E.; Witjens, P. H. Researches on the alkoxy-amino-nitrobenzenes II. Synthesis and taste of the ten possible ethoxy and n-propoxy compounds. Some remarks concerning the problem of the relation between taste and constitution. Rec. trav. chim. 1946, 65, 361-379.
30.Mehta, L. K.; Parrick, J.; Payne, F. The elimination of an alkoxy group in the photo-Graebe–Ullmann conversion of 1-(2,5-dialkoxyphenyl)triazolopyridines into carbolines, and the preparation of α-, γ- and δ-carboline quinones. J. Chem. Soc., Perkin Trans. 1993, 1, 1261-1267.
31.Norris, D. J.; Balog, J. A.; Gavai, A. V.; Austin, J. F.; Han, W. C.; Nation, A. J.; Zhao, Y.; Shan, W. Fused heterocyclic compounds useful as modulators of nuclear hormone receptor function. WO2009003077 (A1), 2008.
dc.identifier.urihttp://tdr.lib.ntu.edu.tw/jspui/handle/123456789/15994-
dc.description.abstract本論文以4-(4-胺苯基)-1-(4-溴苯甲基)-7-甲氧基喹唑啉-2-酮 (16) 的PDE4/5雙效抑制,及在主結構喹唑啉-2-酮的第六位置接上一個溴原子的化合物15a-b為先導化合物,期望能發展成具有選擇性的PDE5抑制劑,來治療臨床上,像是勃起功能障礙、良性攝護腺肥大等等疾病。為了進一步探討在主環第六位置接上溴原子的化合物的結構與活性關係,在這些目標化合物的合成策略中,主結構4-芳香基-喹唑啉-2-酮可經由一系列反應生成的格林納試劑,再與含溴的苯甲腈化合物以及氯甲酸甲酯進行合環反應獲得,目標化合物則由4-芳香基-喹唑啉-2-酮衍生物進行烷基化即可得到。根據體外酵素活性測試結果顯示,在主環第一位置氮上的苯甲基環,如果將拉電子基移到間位位置上,可維持對PDE5的抑制能力,但也會些微抑制PDE6,而同時在鄰位與對位上作拉電子基取代,發現對整體的抑制效果沒有太大的影響,但如果將其以其它疏水性基團如六元環作為取代,發現可以選擇性抑制PDE5。在第四位置苯環上則以對位胺基、甲胺基和間位甲氧基取代有較好的抑制效果,其立體障礙的大小也是影響的關鍵之一。而如果在第六位置置入碘原子取代,可以維持PDE5的抑制能力,但也增強了PDE4和6的抑制效果,足見此位置在對PDE5選擇性上扮演了重要的關鍵角色。此外,在第七位置上的修飾,得知此位置所能容忍的取代基大小有限,最後發現以三氟甲氧基的取代,不論在選擇性還是抑制程度上,都表現的非常卓越。綜觀來說,結合六元環和三氟甲氧基取代的化合物54a,是這一系列化合物中最強效的PDE5抑制劑。zh_TW
dc.description.abstract4-(4-Aminophenyl)-1-(4-bromobenzyl)-7-methoxy-1H-quinazolin-2-one (16), a potential dual PDE4/5 inhibitor, and compounds 15a-b which contain bromo atom on the 6-position of 1H-quinazolin-2-one were chosen as lead compounds for this investigation as potential PDE5 selective inhibitors. These selective inhibitors may be used to treat clinical diseases, such as erectile dysfunction, benign prostatic hyperplasia, etc. To explore further structure-activity relationship, the main structure, 4-aryl-1H- quinazolin-2-ones, were prepared from phenylation, followed by the cyclization of bromo substituted o-aminobenzonitriles and methyl chloroformate. Final tartget compounds were synthesized from alkylation of 4-aryl-1H-quinazolin- 2-ones. According to preliminary result of in vitro enzyme inhibitory activity assay, if the electro-withdrawing group was introduced to the meta position on benzyl ring of the 1-position of main structure, the ability of inhibition on PDE5 will be maintained, but the inhibition of PDE6 will be slightly increased. However, it has no significant effect when the electro-withdrawing groups were placed to ortho and para position at the same time. Moreover, it also has been found that the replacement of other hydrophobic substitution on the 1-position like cyclohexylmethyl ring shows good selectivity on PDE5 with moderate potency. The amino, methylamine group on para and methoxy group on meta position in the benzene ring of 4-position of the main structure show better inhibiton, and the steric hindrance here also plays a vital role in this position. If the iodo atom was placed to the 6-position of the main ring, it will not only enhance the ability of inhibiton on PDE5, but also on PDE4 and 6. So it is reasonable to conclude that this position plays an important role in attaining selectivity on PDE5. Furthermore, the modification on 7-position indicated that it has limitless on the size of substitution here. Finally, the trifluoromethoxy group on 7-position lead to the amazing selectivity and inhibiton on PDE5.In summary, compound 54a with the substitution of trifluoromethoxy group and cyclohexylmethyl ring is the most potent PDE5 inhibitors in this series of compounds.en
dc.description.provenanceMade available in DSpace on 2021-06-07T17:57:29Z (GMT). No. of bitstreams: 1
ntu-101-R99423015-1.pdf: 20866263 bytes, checksum: a8dcb5a419460f68687f9b10c61f2560 (MD5)
Previous issue date: 2012
en
dc.description.tableofcontents目錄……………………………………………………………………i
圖目錄…………………………………………………………………iii
表目錄…………………………………………………………………iv
式目錄……………………………………………………………………v
縮寫表…………………………………………………………………vi
中文摘要………………………………………………………………vii
Abstract………………………………………………………………viii
第一章 緒論……………………1
1.1磷酸二酯酶……………………………………………………………1
1.2第五型磷酸二酯酶……………………………………………………5
1.2.1第五型磷酸二酯酶抑制劑於勃起功能障礙之應用………………5
1.2.2第五型磷酸二酯酶抑制劑在其他疾病治療之應用與其相關研究……7
第二章 實驗目的與設計……………………………………………9
2.1設計動機與目的………………………………………………………9
2.2設計方法……………………………………………………………10
第三章 結果和討論…………………………………………………13
3.1標的化合物之合成…………………………………………………13
3.1.1 4-Phenyl-1-benzyl-1H-quinazolin-2-one衍生物之合成…13
3.2體外酵素活性評估…………………………………………………27
第四章 結論…………32
第五章 實驗部分…………33
5.1實驗儀器和檢驗方法………………………………………………33
5.2試藥與溶劑…………………………………………………………34
5.3合成步驟……………………………………………………………34
5.4體外酵素活性評估…………………………………………………91
參考文獻………………………………………………………………93
附錄……………………………………………………………………97
dc.language.isozh-TW
dc.subject唑啉zh_TW
dc.subject第五型磷酸二酯酶zh_TW
dc.subject-2-酮zh_TW
dc.subject喹zh_TW
dc.subject1H-Quinazolin-2-oneen
dc.subjectPhosphodiesteraseⅤInhibitorsen
dc.title設計與合成喹唑啉-2-酮衍生物作為潛能第五型磷酸二
酯酶抑制劑之可行性評估
zh_TW
dc.titleDesign, Synthesis and Feasibility Evaluation of 1H-Quinazolin-2-one Derivatives as Potential
PhosphodiesteraseⅤInhibitors
en
dc.typeThesis
dc.date.schoolyear100-2
dc.description.degree碩士
dc.contributor.oralexamcommittee王光昭,顧記華,尤啟冬,陳香惠,忻凌偉
dc.subject.keyword喹,唑啉,-2-酮,第五型磷酸二酯酶,zh_TW
dc.subject.keyword1H-Quinazolin-2-one,PhosphodiesteraseⅤInhibitors,en
dc.relation.page166
dc.rights.note未授權
dc.date.accepted2012-08-14
dc.contributor.author-college醫學院zh_TW
dc.contributor.author-dept藥學研究所zh_TW
顯示於系所單位:藥學系

文件中的檔案:
檔案 大小格式 
ntu-101-1.pdf
  未授權公開取用
20.38 MBAdobe PDF
顯示文件簡單紀錄


系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。

社群連結
聯絡資訊
10617臺北市大安區羅斯福路四段1號
No.1 Sec.4, Roosevelt Rd., Taipei, Taiwan, R.O.C. 106
Tel: (02)33662353
Email: ntuetds@ntu.edu.tw
意見箱
相關連結
館藏目錄
國內圖書館整合查詢 MetaCat
臺大學術典藏 NTU Scholars
臺大圖書館數位典藏館
本站聲明
© NTU Library All Rights Reserved